
544B

273/ A method of inhibiting apoptosis in a cell comprising providing the cell with a nucleic acid segment encoding a human sentrin-1 polypeptide.

- 74. The method of claim 73, wherein the nucleic acid segment is further defined as encoding a human sentrin-1 polypeptide that is at least 85% identical to SEQ ID NO:2.
- 75. The method of claim 74, wherein the nucleic acid segment is further defined as encoding a human sentrin-1 polypeptide that is at least 95% identical to SEQ ID NO:2.
- 76. The method of claim 73, wherein the nucleic acid segment is further defined as encoding a polypeptide comprising an amino acid sequence having at least 20 contiguous amino acids of SEQ ID NO:2.
- 77. The method of claim 76, wherein the nucleic acid segment is further defined as encoding a polypeptide comprising an amino acid sequence having at least 30 contiguous amino acids of SEQ ID NO:2.
- 78. The method of claim 77, wherein the nucleic acid segment is further defined as encoding a polypeptide comprising an amino acid sequence having at least 40 contiguous amino acids of SEQ ID NO:2.
- 79. The method of claim 78, wherein the nucleic acid segment is further defined as encoding a polypeptide comprising an amino acid sequence having at least 50 contiguous amino acids of SEQ ID NO:2.
- 80. The method of claim 79, wherein the nucleic acid segment is further defined as encoding a polypeptide comprising an amino acid sequence having at least 60 contiguous amino acids of SEQ ID NO:2.

A2 cont.

- 81. The method of claim 80, wherein the nucleic acid segment is further defined as encoding a polypeptide comprising an amino acid sequence having at least 70 contiguous amino acids of SEQ ID NO:2.
- 82. The method of claim 81, wherein the nucleic acid segment is further defined as encoding a polypeptide comprising an amino acid sequence having at least 80 contiguous amino acids of SEQ ID NO:2.
- 83. The method of claim 82, wherein the nucleic acid segment is further defined as encoding a polypeptide comprising an amino acid sequence having at least 90 contiguous amino acids of SEQ ID NO:2.
- 84. The method of claim 83, wherein the nucleic acid segment is further defined as encoding a polypeptide comprising an amino acid sequence having at least 100 contiguous amino acids of SEQ ID NO:2.
- 85. The method of claim 84, wherein the nucleic acid segment is further defined as encoding a polypeptide comprising SEQ ID NO:2.
- 86. The method of claim 73, wherein the cell is comprised within an animal.
- 87. The method of claim 86, wherein the animal is a human.
- 88. The method of claim 86, wherein the nucleic acid segment is provided to the animal in an amount effective to prevent apoptosis of the cell.
- 89. The method of claim 86, wherein the nucleic acid is provided in a pharmaceutical excipient.



The method of claim 90, wherein the nucleic acid segment is comprised within a vector.

A method of inhibiting apoptosis in a cell comprising providing the cell with a nucleic acid segment comprising at least about 50 contiguous nucleotides of SEQ ID NO:1.

- 93. The method of claim 92, wherein the nucleic acid segment further comprises at least about 100 contiguous nucleotides of SEQ ID NO:1.
- 94. The method of claim 93, wherein the nucleic acid segment further comprises at least about 200 contiguous nucleotides of SEQ ID NO:1.
- 95. The method of claim 94, wherein the nucleic acid segment further comprises at least SEQ ID NO:1.
- 96. The method of claim 92, wherein the cell is comprised within an animal.
- 97. The method of claim 96, wherein the animal is a human.
- 98. The method of claim 96, wherein the nucleic acid segment is provided to the animal in an amount effective to prevent apoptosis of the cell.
- 99. The method of claim 96, wherein the nucleic acid is provided in a pharmaceutical excipient.
- 100. The method of claim 92, wherein the nucleic acid segment is operatively linked to a promoter that expresses the nucleic acid in the cell to provide the polypeptide.